Mike Tyson just dropped a headline on The Katie Miller Podcast—he says he’s expecting good news on cannabis rescheduling. Coming only weeks after President Trump said he would make a decision on cannabis “soon,” Tyson’s comments land at an interesting moment in the national conversation. In this episode of TDR Cannabis in Five presented by Dutchy, host Shadd Dales breaks down Tyson’s remarks, the platform he chose, and why the timing stands out. From calling cannabis “medicine” to saying it helps athletes relax and even “play better,” Tyson’s words add both cultural and political weight to the debate. We also look at the broader context: Trump’s August 11 comments, national media coverage from the Wall Street Journal and the New York Post earlier this summer, and how Tyson’s advocacy fits into a pattern of public appearances, letters, and behind-the-scenes conversations. At the end of the day, this is about understanding the moment. Tyson is optimistic, the media attention is there, and the White House has already said a decision is coming soon. Nothing is guaranteed until it happens—but it’s worth paying attention to voices like Tyson’s as the conversation continues to unfold.
1 Like
Rescheduling it to schedule 3 will kill the dispensary model because pharmacies will start dispensing it
2 Likes
Good, dispensaries suck
3 Likes
couldnt agree more
2 Likes
It’s going to be higher quality shit from the pharmacy probably.
WAY more regulation on a pharmacy than a dispensary
1 Like
So THC will be next to the Tylenol on the shelf?
Under the Controlled Substances Act, a Schedule III classification is for drugs with a moderate to low potential for physical and psychological dependence.
As of April 23, 2026, the Trump administration has officially moved FDA-approved marijuana products and state-licensed medical marijuana into this category, moving them out of the highly restrictive Schedule I (which includes heroin and LSD).
The federal government now formally acknowledges that medical marijuana has currently accepted medical use. Licensed medical marijuana businesses can now claim standard federal tax deductions, as they are no longer subject to IRS Section 280E.
Scientists no longer need an onerous Schedule I license to study the plant, which is expected to accelerate clinical trials on safety and efficacy.
It is not legalization. Marijuana remains a federally controlled substance; only the severity of the restrictions has changed. Recreational (adult-use) marijuana that is not part of a state-licensed medical program remains in Schedule I for now.
Marijuana now sits alongside these other substances:
- Ketamine (anesthetic)
- Anabolic steroids and testosterone
- Tylenol with codeine (containing less than 90mg of codeine per dose)
- Buprenorphine (Suboxone)
The Department of Justice has scheduled further hearings for late June 2026 to consider if this classification should be extended to all marijuana products